SELLAS Life Sciences (SLS) Assets Average (2011 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Assets Average of $96.3 million for Q1 2026, up 253.98% year-over-year from $27.2 million in Q1 2025, and up 48.21% quarter-over-quarter from $65.0 million in Q4 2025.
SELLAS Life Sciences (SLS) Assets Average (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Assets Average for 16 consecutive years, with $96.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 253.98% year-over-year to $96.3 million; the TTM figure through Mar 2026 stood at $96.3 million (up 253.98% YoY), while the FY2025 annual figure was $48.9 million, up 281.18% from the prior year.
- Assets Average improved to $96.3 million in Q1 2026 per SLS's latest filing, from $65.0 million in the prior quarter.
- Across five years, Assets Average topped out at $96.3 million in Q1 2026 and bottomed at $7.2 million in Q4 2023.
- Historically, Assets Average has averaged $30.3 million across 5 years, with a median of $23.9 million in 2022.
- Annual changes were most pronounced in 2023 — Assets Average plunged 69.53% — and 2026, when it surged 253.98%.
- SELLAS Life Sciences' Assets Average stood at $23.5 million in 2022, then slumped by 69.53% to $7.2 million in 2023, then surged by 221.13% to $23.0 million in 2024, then surged by 182.78% to $65.0 million in 2025, then jumped by 48.21% to $96.3 million in 2026.
- Business Quant data shows SLS's Assets Average at $96.3 million in Q1 2026, $65.0 million in Q4 2025, and $41.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 129.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129.78 Mn |
| Mar 31, 2026 | 96.26 Mn |
| Dec 31, 2025 | 64.95 Mn |
| Sep 30, 2025 | 41.93 Mn |
| Jun 30, 2025 | 33.63 Mn |
| Mar 31, 2025 | 27.19 Mn |
| Dec 31, 2024 | 22.97 Mn |
| Sep 30, 2024 | 20.81 Mn |
| Jun 30, 2024 | 19.78 Mn |
| Mar 31, 2024 | 15.33 Mn |
| Dec 31, 2023 | 7.15 Mn |
| Sep 30, 2023 | 13.33 Mn |
| Jun 30, 2023 | 23.84 Mn |
| Mar 31, 2023 | 25.02 Mn |
| Dec 31, 2022 | 23.47 Mn |
| Sep 30, 2022 | 29.11 Mn |
| Jun 30, 2022 | 26.82 Mn |
| Mar 31, 2022 | 23.85 Mn |
| Dec 31, 2021 | 32.11 Mn |
| Sep 30, 2021 | 40.79 Mn |